Alzheimer's disease (AD) is the most prevalent neurodegenerative disease in ageing,
affecting around 46 million people worldwide but few treatments are currently available. The …

Patients with Alzheimer's disease (AD) present with both extracellular amyloid-β (Aβ)
plaques and intracellular tau-containing neurofibrillary tangles in the brain. For many years …

Introduction The overall goal of the Alzheimer's Disease Neuroimaging Initiative (ADNI) is to
validate biomarkers for Alzheimer's disease (AD) clinical trials. ADNI is a multisite …

Herpes simplex virus-1 (HSV-1) establishes latency preferentially in sensory neurons of
peripheral ganglia. A variety of stresses can induce recurrent reactivations of the virus …

Background 18 F-THK5351 is a quinoline-derived tau imaging agent with high affinity to
paired helical filaments (PHF). However, high levels of 18 F-THK5351 retention in brain …

Negative psychological and physiological consequences of neurodegenerative disorders
represent a high social and health cost. Among the neurodegenerative disorders …

Tracking longitudinal tau tangles accumulation across the Alzheimer's disease continuum is
crucial to better understand the natural history of tau pathology and for clinical trials …

Background Imaging agents capable of quantifying the brain's tau aggregates will allow a
more precise staging of Alzheimer's disease (AD). The aim of the present study was to …

Abstract 18 F-fluoroethoxybenzovesamicol (FEOBV) is a new PET radiotracer that binds to
the vesicular acetylcholine transporter. In both animals and healthy humans, FEOBV was …

Alzheimer's disease (AD) pathology is commonly associated with cognitive decline but is
also composed of neuropsychiatric symptoms including psychological distress and …